Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Soricimed Biopharma Inc
- Target Recruit Count
- 23
- Registration Number
- NCT01578564
- Locations
- 🇨🇦
Juravinski Cancer Center, Hamilton, Ontario, Canada
🇨🇦London Health Sciences Centre, London, Ontario, Canada
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath